Proteotype's Revolutionary Venture in Early Cancer Detection
Proteotype Diagnostics Ltd, in partnership with the University of Southampton, has secured £1.5 million in funding from the National Institute for Health and Care Research (NIHR) and the Office for Life Sciences (OLS). This notable grant will drive the clinical validation of the innovative Enlighten® Multi-Cancer Early Detection test, which represents a significant advancement in the detection of early-stage cancers.
Understanding the Enlighten® Test
Unlike many traditional cancer diagnostics that rely on signals emitted by tumors, such as circulating tumor DNA that typically becomes detectable only when cancer has advanced, Enlighten® offers a novel approach. This innovative test evaluates the body's host response to tumor development by monitoring fluctuations in protein levels detectable even in the earliest cancer stages.
Promising Results from Recent Trials
Initial findings have shown great promise. During the recent AACR conference, Proteotype announced an impressive detection rate of 86% across various cancers, alongside a remarkable 0% false-positive rate. These results reinforce the test's efficacy, particularly for early-stage cancers. A larger patient group will soon undergo testing for more robust performance analysis.
Advancing Health Equity through Targeted Trials
The Enlighten® test is set to be tested in real-world NHS settings with an aim to reach higher-risk populations often underserved by current diagnostic methods. The MODERNISED clinical study, under the leadership of Professor Andrew Davies at the University of Southampton Experimental Cancer Medicine Centre, is poised to recruit 1,350 participants, particularly targeting cancers that afflict socio-economically deprived areas, including colorectal and lung cancers.
Inspirational Personal Commitment
Wesley Sukdao, co-founder and CEO of Proteotype Diagnostics, shared a compelling personal story to underscore the necessity of equitable health solutions. Growing up in impoverished conditions, he experienced the devastating impacts of late cancer detection as several close family members lost their lives to the disease. He emphasized that innovative cancer diagnostics must be affordable and accessible to generate meaningful change in health inequality.
Cost-Effective Screening Solutions
The Enlighten® test is structured to ensure that it does not require costly, specialized equipment or supplies. Instead, it uses affordable laboratory kits designed for easy adaptation to patient plasma, facilitating large-scale screening efforts. These kits ensure rapid results, often available within just 24 hours of sample analysis, making the test a viable option for comprehensive adoption by NHS frameworks.
Economic Evaluation for Sustainable Implementation
The MODERNISED study will include a Health Economic Evaluation, focusing on ensuring that the Enlighten® test not only demonstrates clinical benefits but also aligns with NHS financial objectives.
A Step Forward in Cancer Screening
This grant is part of a broader UK Government initiative, committing £22.5 million to enhance the OLS Cancer Programme. The milestone represents a commitment to further developing the Enlighten® test and will facilitate its regulatory approval and potential integration into existing NHS cancer screening programs.
Expert Insights on the Innovation
Professor Andrew Davies, the Chief Investigator for the MODERNISED project, expressed confidence in the innovation, stating that if successful, Enlighten could represent a transformative leap in early cancer diagnostics by effectively capturing the subtle protein changes within the bloodstream that precede clear symptoms of cancer.
About Proteotype Diagnostics Ltd
Proteotype is recognized as a pioneering diagnostics company dedicated to creating advanced multi-cancer early detection tests and personalized medicine solutions. With a focus on leveraging sophisticated technology and comprehensive research, Proteotype is on a mission to fundamentally reshape cancer diagnostics, thereby improving early detection capabilities and overall patient outcomes.
Frequently Asked Questions
What is the Enlighten® test?
The Enlighten® test is an innovative multi-cancer early detection method that assesses the body's host response to tumor development.
How much funding did Proteotype receive?
Proteotype has been awarded £1.5 million for the clinical validation of the Enlighten® test.
What were the preliminary results of the Enlighten® test?
Preliminary results indicated an 86% detection rate for multiple cancers with a 0% false-positive rate.
What populations will be targeted during the trials?
The trials will focus on reaching underserved populations, particularly in low-socioeconomic areas with high cancer mortality rates.
What is the ultimate goal of the Enlighten® test?
The ultimate goal is to achieve early cancer detection, which can increase treatment options and improve patient outcomes.
